Saturday 17 October 2026
Export IMNN’s income statement to Excel — free account
Imunon, Inc.
IMNN Healthcare Biotechnology
Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.02
0.04
−3.77%
Follow IMNN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(233.50%) | (256.41%) | (768.26%) | (641.02%) | |
| (122.58%) | (131.74%) | (196.78%) | (123.93%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (324.37%) | |
Return on Tangible Assets |
(391.39%) | (218.63%) | (502.35%) | (337.03%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(5.08) | (6.68) | (2.99) | (2.90) | |
Free Cash Flow |
(14.95) | (14.18) | (15.03) | (15.20) | |
Capital Expenditures |
(0.29) | (0.28) | — | (0.09) | |
| Other line items | |||||
Cash ROIC |
(160.22%) | (89.49%) | (184.39%) | (91.63%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | — | (27.54) | |
Operating CF/Net income |
1.02 | 0.96 | 1.03 | 1.03 | |
Depreciation/Fixed assets |
1.16 | 1.32 | 1.45 | 1.56 | |
Capex/Depreciation |
(0.42) | (0.40) | 0.00 | (0.13) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.98) | (6.54) | (2.99) | (2.89) | |
Capex per Share |
(0.10) | (0.13) | 0.00 | (0.02) | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates